摘要
目的:探讨表柔比星联合环磷酰胺对MDA-MB-231细胞成瘤性及其对肿瘤中细胞质膜微囊蛋白-1(caveolin-1)表达的影响。方法:以乳腺癌MDA-MB-231细胞建立裸鼠移植瘤模型,实验分为表柔比星组、环磷酰胺组、表柔比星+环磷酰胺组(联合用药组)和对照组(注射等体积0.9%氯化钠溶液),采用免疫组织化学法检测移植瘤中caveolin-1表达,以图像信号采集与分析系统进行图像扫描分析。结果:表柔比星组、环磷酰胺组和联合用药组的抑瘤率分别为31.28%、33.42%和66.14%。免疫组织化学法显示给药组肿瘤组织中caveolin-1表达明显增强,caveolin-1在联合用药组(253.22±38.52)肿瘤组织中表达较对照组(31.73±2.28)和表柔比星组(157.52±32.69)、环磷酰胺组(148.23±41.66)明显增强,图像灰度值统计分析显示差异有统计学意义(P<0.05)。结论:表柔比星和环磷酰胺可抑制乳腺癌肿瘤细胞生长,二者联用抑瘤作用增强,肿瘤生长体积与caveolin-1的表达呈反向性,提示二者之间可能在抑瘤机制上存在相关性。
Objective： To investigate the effects of epirubicin combined with cyclophosphamide on tumor formation and the expression of caveolin-1 in MDA-MB-231 breast cancer cells. Methods： Human breast cancer xenografts in nude mice were established by using MDA-MB-231 cells. Epirubicin group, cyclophosphamide group, and epirubicin＋cyclophosphamide group, and saline control group were set up. By using immunohistochemistry the expression of caveolin-1 was detected in xenografts. Image signal acquisition and analysis system was applied for image scanning analysis. Results： The rate of tumor suppressor in epirubicin group, cyclophosphamide group and epirubicin＋cyclophosphamide group was 31.28%, 33.42% and 66.14% respectively. Immunohistochemistry demonstrated that the caveolin-1 expression in epirubicin＋cyclophosphamide group（253.22±38.52） was significantly increased compared with saline control group（31.73±2.28）, epirubicin group（157.52±32.69） and cyclophosphamide group（148.23±41.66）（P〈0.05）. Conclusion： Epirubicin and cyclophosphamide can inhibit the growth of MDA-MB-231 cells with a synergic effect. The caveolin-1 expression is increased significantly in epirubicin＋cyclophosphamide group, indicating caveolin-1 protein may play an important role in tumor cells growth.
出处
《温州医科大学学报》
CAS
2017年第1期33-36,共4页
Journal of Wenzhou Medical University
基金
温州市科技计划项目(Y20160420)
